FDA Assessing QT Study Designs With Clinical Trial Simulations
Executive Summary
FDA hopes to use clinical trial simulations to develop study designs to more accurately predict drugs' QT prolongation risk
You may also be interested in...
CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities
FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates
Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer
Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies
CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities
FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates